Non-steroidal Anti-inflammatory Drugs Market by Drug Class (Acetic Acid Derivatives, Fenamates, Oxicams), Formulation (Capsules, Creams/Gels, Powders), Route Of Administration, Prescription Status, Release Type, Patient Group, Indication, End User, Distri
Description
The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 23.14 billion in 2024 and is projected to grow to USD 24.62 billion in 2025, with a CAGR of 6.67%, reaching USD 38.81 billion by 2032.
Comprehensive foundational overview of therapeutic, regulatory, and commercial dynamics shaping NSAID utilization and strategic decision-making in healthcare markets
Non-steroidal anti-inflammatory drugs (NSAIDs) remain a cornerstone of pain and inflammation management across clinical and consumer settings, with clinical practice and patient preferences continuing to evolve in tandem with regulatory scrutiny and formulation innovation. This introduction synthesizes the current therapeutic positioning of NSAIDs, highlighting how safety considerations, alternative analgesic pathways, and patient demand for targeted delivery formats are reshaping prescribing and purchasing behavior. It frames the broader landscape by discussing how clinical evidence, adverse event monitoring, and changing healthcare delivery models intersect to influence product development and commercialization strategies.
Readers will find an integrated account of the operational environment that pharmaceutical developers and commercial teams must navigate. The narrative connects pharmacologic mechanisms and therapeutic indications to commercial levers such as channel strategy, formulation differentiation, and regulatory engagement. By establishing this baseline, the section prepares stakeholders to interpret subsequent discussions on competitive dynamics, supply chain vulnerabilities, and the strategic imperatives required to maintain relevance in a complex, safety-sensitive therapeutic class.
Deep analysis of the converging scientific, regulatory, and commercial forces reshaping NSAID formulation strategies, safety narratives, and channel dynamics
The NSAID landscape is undergoing transformative shifts driven by scientific, regulatory, and consumer-facing forces that collectively alter competitive dynamics and product priorities. Advances in formulation science are expanding the role of topical and transdermal delivery platforms, which offer localized efficacy with reduced systemic exposure and improved tolerability for certain patient cohorts. Simultaneously, evolving safety data and post-market surveillance have prompted clinicians and regulators to re-evaluate risk–benefit profiles, especially for patients with cardiovascular risk factors, creating a premium on differentiation through safety data and patient-centric labeling.
Concurrently, digital channels and e-commerce growth are changing how consumers discover and purchase over-the-counter analgesics, while telehealth expansion influences prescription pathways. Manufacturers are responding by accelerating investments in real-world evidence generation, digital patient engagement, and therapeutic area education to sustain trust and uptake. In addition, manufacturers and suppliers are prioritizing supply chain agility and regional manufacturing partnerships to mitigate geopolitical and trade-related disruptions. Together, these shifts emphasize the need for integrated strategies that combine clinical credibility with commercial adaptability to sustain long-term market position.
Holistic assessment of how United States tariff shifts through 2025 have materially influenced NSAID supply chains, sourcing strategies, and commercial resilience
The cumulative impact of recent tariff developments in the United States through 2025 has introduced a new layer of complexity to sourcing, pricing, and manufacturing strategies for NSAID manufacturers and distributors. Tariff-related cost pressures have compelled many organizations to re-evaluate supplier relationships, accelerate nearshoring initiatives, and pass through selective costs to channel partners where competitive positioning allows. In practice, this has resulted in procurement teams increasing emphasis on multi-sourcing, flexible contract terms, and inventory buffering to maintain continuity of supply and manage margin volatility.
Beyond direct cost effects, tariffs have also influenced investment decisions related to capital equipment, sterile manufacturing capacity, and finished-dosage-form production. Firms with vertically integrated capabilities have been better able to absorb or offset marginal tariff impacts, while those reliant on single-region suppliers faced more acute margin compression. Regulatory compliance and customs administration requirements have added administrative complexity, necessitating enhanced trade oversight and cross-functional coordination between procurement, regulatory affairs, and commercial teams. Taken together, tariff-driven dynamics have elevated supply chain strategy from an operational focus to a core strategic priority for industry leaders.
Strategic segmentation insights linking channels, administration routes, drug classes, formulations, and end-user settings to actionable product and go-to-market differentiation
Segmentation analysis reveals divergent pathways of value capture across distribution channels, routes of administration, drug classes, formulations, and end-user settings that together define competitive opportunity. Based on Distribution Channel, market is studied across Over The Counter and Prescription, which highlights distinct go-to-market imperatives: consumer marketing and shelf visibility for the OTC space versus formulary access, clinical evidence, and physician engagement for prescription therapies. Based on Route Of Administration, market is studied across Oral, Parenteral, and Topical, underscoring how localized therapies and injectable options require different clinical positioning, manufacturing capabilities, and regulatory dossiers.
Based on Drug Class, market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, a segmentation that frames safety profiles, differentiation opportunities, and prescriber preferences. Based on Formulation, market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, which draws attention to the role of excipients, delivery technologies, and patient adherence factors in determining product selection. Based on End User, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, indicating how procurement cycles, purchasing authority, and service expectations vary across institutional and consumer channels. By aligning product development, regulatory strategy, and commercial execution with these segmentation lenses, stakeholders can pinpoint where to invest in clinical evidence, manufacturing capacity, and channel-specific marketing to maximize therapeutic and economic impact.
In-depth regional intelligence showing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics drive regulatory strategy, manufacturing footprints, and channel deployment
Regional dynamics continue to exert a profound influence on competitive strategy, regulatory navigation, and supply chain decisions across the principal global blocs of Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, diverse healthcare reimbursement systems and robust OTC markets demand tailored channel strategies that address payer policies, retail pharmacy relationships, and consumer health education. Emerging regional manufacturing hubs are also shifting where finished-dosage forms and intermediates are produced, which in turn affects lead times and risk exposure.
The Europe, Middle East & Africa cluster presents a heterogeneous regulatory environment in which harmonization efforts coexist with country-specific approval pathways and safety reporting expectations. This complexity favors organizations that maintain strong regulatory affairs capabilities and local partnerships. In the Asia-Pacific region, rapid urbanization, expanding healthcare access, and growing e-commerce adoption are accelerating consumer demand for accessible analgesic options and stimulating investment in localized manufacturing and formulation innovation. Taken together, regional considerations should inform decisions on clinical trial localization, regulatory sequencing, and distribution investments to optimize access and margin performance across markets.
Comprehensive competitive analysis revealing how established manufacturers, generics specialists, and formulation innovators compete through partnerships, evidence, and manufacturing agility
Competitive dynamics among key companies illustrate a balance between legacy pharmaceutical players, specialized generics manufacturers, and innovative formulators that together drive product evolution. Established pharmaceutical companies retain advantages in regulatory experience, broad manufacturing networks, and established relationships with institutional buyers, while independent specialists often lead with cost-efficient production, flexible contract manufacturing, and targeted channel penetration. Innovators focusing on topical and transdermal delivery systems are carving differentiated positions by demonstrating improved tolerability and patient adherence in specific indications.
Strategic partnerships, licensing arrangements, and acquisitions remain central mechanisms through which organizations expand therapeutic breadth and manufacturing capacity. At the same time, intellectual property landscapes and regulatory exclusivities continue to advantage those with robust clinical programs and patent portfolios. Companies that prioritize post-market safety surveillance, evidence generation, and transparent communication tend to preserve prescriber trust and sustain uptake. Competitors are also increasingly leveraging digital engagement and real-world data to demonstrate comparative value and support market access discussions with payers and large institutional purchasers.
Actionable, high-impact recommendations for leaders to strengthen supply resilience, accelerate formulation innovation, and optimize channel-specific commercial strategies
Industry leaders should adopt a set of pragmatic, high-impact actions to strengthen market position, protect margins, and accelerate innovation across NSAID portfolios. First, prioritize diversification of sourcing and manufacturing footprints to reduce tariff and geopolitical exposure while improving lead-time flexibility; pursuing regional contract manufacturing partnerships and selective nearshoring can materially reduce disruption risk. Second, invest in topical and localized delivery research programs to capture demand driven by safety-conscious prescribers and patients seeking targeted relief with reduced systemic exposure.
Third, expand digital and omnichannel engagement to support direct-to-consumer education and to streamline prescription-to-delivery pathways, with an emphasis on data capture to inform iterative product improvement. Fourth, deepen commitment to real-world evidence and pharmacovigilance to differentiate products on demonstrable safety and effectiveness metrics that matter to prescribers and payers. Fifth, align commercial strategies by channel: consumer-centric branding and retail execution for OTC offerings, and clinical outcomes and formulary value articulation for prescription products. These measures, taken in an integrated manner, provide a roadmap for sustaining growth while managing regulatory and commercial complexity.
Robust mixed-method research approach integrating expert interviews, regulatory and clinical evidence review, and rigorous data triangulation to ensure actionable insights
The research underpinning this report draws on a multi-method design that integrates primary engagements with subject-matter experts and secondary interrogation of regulatory filings, clinical literature, patent records, and supply chain data. Primary research included structured interviews with clinicians, formulary decision-makers, procurement leads, and commercial executives to capture practice patterns, purchasing rationales, and channel dynamics. Secondary research entailed systematic review of public regulatory documents, peer-reviewed clinical studies, manufacturing registries, and trade publications to triangulate primary findings and validate strategic implications.
Analytical protocols employed data triangulation to reconcile potentially divergent inputs, and quality assurance steps ensured consistency across geographies and product classes. Scenario analysis and sensitivity checks were applied to stress-test strategic recommendations against a range of operational disruptions, regulatory changes, and channel evolution narratives. Throughout, ethical standards for data use and respondent confidentiality were maintained to protect proprietary insights. This mixed-method approach yields a robust, practical evidence base tailored to support policy, investment, and commercial decision-making.
Conclusive synthesis of strategic imperatives emphasizing evidence-driven differentiation, manufacturing agility, and coordinated commercial execution for sustained NSAID relevance
In conclusion, the modern NSAID landscape presents both enduring therapeutic utility and emergent complexity driven by safety considerations, formulation innovation, evolving channels, and trade-related supply risks. Stakeholders who integrate clinical credibility with agile manufacturing and channel strategies are best positioned to navigate these complexities and deliver therapeutic value across diverse patient populations. Continued investment in differentiated delivery systems, real-world evidence, and digital engagement will underpin future competitive advantage while robust trade and procurement strategies will shield operations from external shocks.
Ultimately, success in this therapeutic class will hinge on the ability to align clinical evidence generation with pragmatic commercialization plans that respect regional regulatory nuance, end-user preferences, and channel-specific dynamics. Organizations that maintain cross-functional coordination among R&D, regulatory, supply chain, and commercial teams will accelerate time-to-value and strengthen resilience in an environment where safety, efficacy, and accessibility are simultaneously demanded by clinicians, payers, and patients.
Note: PDF & Excel + Online Access - 1 Year
Comprehensive foundational overview of therapeutic, regulatory, and commercial dynamics shaping NSAID utilization and strategic decision-making in healthcare markets
Non-steroidal anti-inflammatory drugs (NSAIDs) remain a cornerstone of pain and inflammation management across clinical and consumer settings, with clinical practice and patient preferences continuing to evolve in tandem with regulatory scrutiny and formulation innovation. This introduction synthesizes the current therapeutic positioning of NSAIDs, highlighting how safety considerations, alternative analgesic pathways, and patient demand for targeted delivery formats are reshaping prescribing and purchasing behavior. It frames the broader landscape by discussing how clinical evidence, adverse event monitoring, and changing healthcare delivery models intersect to influence product development and commercialization strategies.
Readers will find an integrated account of the operational environment that pharmaceutical developers and commercial teams must navigate. The narrative connects pharmacologic mechanisms and therapeutic indications to commercial levers such as channel strategy, formulation differentiation, and regulatory engagement. By establishing this baseline, the section prepares stakeholders to interpret subsequent discussions on competitive dynamics, supply chain vulnerabilities, and the strategic imperatives required to maintain relevance in a complex, safety-sensitive therapeutic class.
Deep analysis of the converging scientific, regulatory, and commercial forces reshaping NSAID formulation strategies, safety narratives, and channel dynamics
The NSAID landscape is undergoing transformative shifts driven by scientific, regulatory, and consumer-facing forces that collectively alter competitive dynamics and product priorities. Advances in formulation science are expanding the role of topical and transdermal delivery platforms, which offer localized efficacy with reduced systemic exposure and improved tolerability for certain patient cohorts. Simultaneously, evolving safety data and post-market surveillance have prompted clinicians and regulators to re-evaluate risk–benefit profiles, especially for patients with cardiovascular risk factors, creating a premium on differentiation through safety data and patient-centric labeling.
Concurrently, digital channels and e-commerce growth are changing how consumers discover and purchase over-the-counter analgesics, while telehealth expansion influences prescription pathways. Manufacturers are responding by accelerating investments in real-world evidence generation, digital patient engagement, and therapeutic area education to sustain trust and uptake. In addition, manufacturers and suppliers are prioritizing supply chain agility and regional manufacturing partnerships to mitigate geopolitical and trade-related disruptions. Together, these shifts emphasize the need for integrated strategies that combine clinical credibility with commercial adaptability to sustain long-term market position.
Holistic assessment of how United States tariff shifts through 2025 have materially influenced NSAID supply chains, sourcing strategies, and commercial resilience
The cumulative impact of recent tariff developments in the United States through 2025 has introduced a new layer of complexity to sourcing, pricing, and manufacturing strategies for NSAID manufacturers and distributors. Tariff-related cost pressures have compelled many organizations to re-evaluate supplier relationships, accelerate nearshoring initiatives, and pass through selective costs to channel partners where competitive positioning allows. In practice, this has resulted in procurement teams increasing emphasis on multi-sourcing, flexible contract terms, and inventory buffering to maintain continuity of supply and manage margin volatility.
Beyond direct cost effects, tariffs have also influenced investment decisions related to capital equipment, sterile manufacturing capacity, and finished-dosage-form production. Firms with vertically integrated capabilities have been better able to absorb or offset marginal tariff impacts, while those reliant on single-region suppliers faced more acute margin compression. Regulatory compliance and customs administration requirements have added administrative complexity, necessitating enhanced trade oversight and cross-functional coordination between procurement, regulatory affairs, and commercial teams. Taken together, tariff-driven dynamics have elevated supply chain strategy from an operational focus to a core strategic priority for industry leaders.
Strategic segmentation insights linking channels, administration routes, drug classes, formulations, and end-user settings to actionable product and go-to-market differentiation
Segmentation analysis reveals divergent pathways of value capture across distribution channels, routes of administration, drug classes, formulations, and end-user settings that together define competitive opportunity. Based on Distribution Channel, market is studied across Over The Counter and Prescription, which highlights distinct go-to-market imperatives: consumer marketing and shelf visibility for the OTC space versus formulary access, clinical evidence, and physician engagement for prescription therapies. Based on Route Of Administration, market is studied across Oral, Parenteral, and Topical, underscoring how localized therapies and injectable options require different clinical positioning, manufacturing capabilities, and regulatory dossiers.
Based on Drug Class, market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, a segmentation that frames safety profiles, differentiation opportunities, and prescriber preferences. Based on Formulation, market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, which draws attention to the role of excipients, delivery technologies, and patient adherence factors in determining product selection. Based on End User, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, indicating how procurement cycles, purchasing authority, and service expectations vary across institutional and consumer channels. By aligning product development, regulatory strategy, and commercial execution with these segmentation lenses, stakeholders can pinpoint where to invest in clinical evidence, manufacturing capacity, and channel-specific marketing to maximize therapeutic and economic impact.
In-depth regional intelligence showing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics drive regulatory strategy, manufacturing footprints, and channel deployment
Regional dynamics continue to exert a profound influence on competitive strategy, regulatory navigation, and supply chain decisions across the principal global blocs of Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, diverse healthcare reimbursement systems and robust OTC markets demand tailored channel strategies that address payer policies, retail pharmacy relationships, and consumer health education. Emerging regional manufacturing hubs are also shifting where finished-dosage forms and intermediates are produced, which in turn affects lead times and risk exposure.
The Europe, Middle East & Africa cluster presents a heterogeneous regulatory environment in which harmonization efforts coexist with country-specific approval pathways and safety reporting expectations. This complexity favors organizations that maintain strong regulatory affairs capabilities and local partnerships. In the Asia-Pacific region, rapid urbanization, expanding healthcare access, and growing e-commerce adoption are accelerating consumer demand for accessible analgesic options and stimulating investment in localized manufacturing and formulation innovation. Taken together, regional considerations should inform decisions on clinical trial localization, regulatory sequencing, and distribution investments to optimize access and margin performance across markets.
Comprehensive competitive analysis revealing how established manufacturers, generics specialists, and formulation innovators compete through partnerships, evidence, and manufacturing agility
Competitive dynamics among key companies illustrate a balance between legacy pharmaceutical players, specialized generics manufacturers, and innovative formulators that together drive product evolution. Established pharmaceutical companies retain advantages in regulatory experience, broad manufacturing networks, and established relationships with institutional buyers, while independent specialists often lead with cost-efficient production, flexible contract manufacturing, and targeted channel penetration. Innovators focusing on topical and transdermal delivery systems are carving differentiated positions by demonstrating improved tolerability and patient adherence in specific indications.
Strategic partnerships, licensing arrangements, and acquisitions remain central mechanisms through which organizations expand therapeutic breadth and manufacturing capacity. At the same time, intellectual property landscapes and regulatory exclusivities continue to advantage those with robust clinical programs and patent portfolios. Companies that prioritize post-market safety surveillance, evidence generation, and transparent communication tend to preserve prescriber trust and sustain uptake. Competitors are also increasingly leveraging digital engagement and real-world data to demonstrate comparative value and support market access discussions with payers and large institutional purchasers.
Actionable, high-impact recommendations for leaders to strengthen supply resilience, accelerate formulation innovation, and optimize channel-specific commercial strategies
Industry leaders should adopt a set of pragmatic, high-impact actions to strengthen market position, protect margins, and accelerate innovation across NSAID portfolios. First, prioritize diversification of sourcing and manufacturing footprints to reduce tariff and geopolitical exposure while improving lead-time flexibility; pursuing regional contract manufacturing partnerships and selective nearshoring can materially reduce disruption risk. Second, invest in topical and localized delivery research programs to capture demand driven by safety-conscious prescribers and patients seeking targeted relief with reduced systemic exposure.
Third, expand digital and omnichannel engagement to support direct-to-consumer education and to streamline prescription-to-delivery pathways, with an emphasis on data capture to inform iterative product improvement. Fourth, deepen commitment to real-world evidence and pharmacovigilance to differentiate products on demonstrable safety and effectiveness metrics that matter to prescribers and payers. Fifth, align commercial strategies by channel: consumer-centric branding and retail execution for OTC offerings, and clinical outcomes and formulary value articulation for prescription products. These measures, taken in an integrated manner, provide a roadmap for sustaining growth while managing regulatory and commercial complexity.
Robust mixed-method research approach integrating expert interviews, regulatory and clinical evidence review, and rigorous data triangulation to ensure actionable insights
The research underpinning this report draws on a multi-method design that integrates primary engagements with subject-matter experts and secondary interrogation of regulatory filings, clinical literature, patent records, and supply chain data. Primary research included structured interviews with clinicians, formulary decision-makers, procurement leads, and commercial executives to capture practice patterns, purchasing rationales, and channel dynamics. Secondary research entailed systematic review of public regulatory documents, peer-reviewed clinical studies, manufacturing registries, and trade publications to triangulate primary findings and validate strategic implications.
Analytical protocols employed data triangulation to reconcile potentially divergent inputs, and quality assurance steps ensured consistency across geographies and product classes. Scenario analysis and sensitivity checks were applied to stress-test strategic recommendations against a range of operational disruptions, regulatory changes, and channel evolution narratives. Throughout, ethical standards for data use and respondent confidentiality were maintained to protect proprietary insights. This mixed-method approach yields a robust, practical evidence base tailored to support policy, investment, and commercial decision-making.
Conclusive synthesis of strategic imperatives emphasizing evidence-driven differentiation, manufacturing agility, and coordinated commercial execution for sustained NSAID relevance
In conclusion, the modern NSAID landscape presents both enduring therapeutic utility and emergent complexity driven by safety considerations, formulation innovation, evolving channels, and trade-related supply risks. Stakeholders who integrate clinical credibility with agile manufacturing and channel strategies are best positioned to navigate these complexities and deliver therapeutic value across diverse patient populations. Continued investment in differentiated delivery systems, real-world evidence, and digital engagement will underpin future competitive advantage while robust trade and procurement strategies will shield operations from external shocks.
Ultimately, success in this therapeutic class will hinge on the ability to align clinical evidence generation with pragmatic commercialization plans that respect regional regulatory nuance, end-user preferences, and channel-specific dynamics. Organizations that maintain cross-functional coordination among R&D, regulatory, supply chain, and commercial teams will accelerate time-to-value and strengthen resilience in an environment where safety, efficacy, and accessibility are simultaneously demanded by clinicians, payers, and patients.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Launch of novel extended-release subcutaneous ibuprofen formulations targeting chronic pain management
- 5.2. Rising development of NSAID-biologic combination therapies to mitigate inflammation with reduced side effects
- 5.3. Expansion of topical diclofenac gel adoption among geriatric patients for localized osteoarthritis relief
- 5.4. Deployment of AI-driven pharmacovigilance platforms to monitor cardiovascular risks associated with NSAID usage
- 5.5. Growth of fixed-dose paracetamol and ibuprofen co-formulations to improve patient adherence in over-the-counter markets
- 5.6. Regulatory acceleration for injectable meloxicam microsphere formulations aimed at postoperative pain control
- 5.7. Increasing investment in green chemistry processes for sustainable manufacturing of non-steroidal anti-inflammatory drugs
- 5.8. Wider adoption of enhanced recovery after surgery protocols driving increased perioperative use of intravenous NSAIDs to reduce opioids
- 5.9. Shift toward retailer private labels and value packs in e-commerce analgesics intensifying price competition for ibuprofen and naproxen
- 5.10. Integration of pharmacogenetic testing for CYP2C9 and CYP2C8 variants to personalize NSAID choice and dosing in high-risk patients
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class
- 8.1. Acetic Acid Derivatives
- 8.1.1. Diclofenac
- 8.1.2. Ketorolac
- 8.2. Fenamates
- 8.2.1. Flufenamic Acid
- 8.2.2. Mefenamic Acid
- 8.3. Oxicams
- 8.3.1. Piroxicam
- 8.3.2. Tenoxicam
- 8.4. Propionic Acid Derivatives
- 8.4.1. Flurbiprofen
- 8.4.2. Ibuprofen
- 8.4.3. Ketoprofen
- 8.4.4. Naproxen
- 8.5. Salicylates
- 8.5.1. Aspirin
- 8.5.2. Diflunisal
- 8.6. Selective COX-2 Inhibitors (Coxibs)
- 8.6.1. Celecoxib
- 8.6.2. Etoricoxib
- 9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation
- 9.1. Capsules
- 9.2. Creams/Gels
- 9.3. Powders
- 9.4. Tablets
- 10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration
- 10.1. Oral
- 10.2. Parenteral
- 10.3. Topical
- 11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status
- 11.1. Over-The-Counter
- 11.2. Prescription Only
- 12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type
- 12.1. Immediate-Release
- 12.2. Modified-Release
- 12.2.1. Controlled-Release
- 12.2.2. Delayed-Release/Enteric-Coated
- 12.2.3. Extended-Release
- 13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group
- 13.1. Adults
- 13.2. Geriatric
- 13.3. Pediatric
- 14. Non-steroidal Anti-inflammatory Drugs Market, by Indication
- 14.1. Acute Pain
- 14.1.1. Dental Pain
- 14.1.2. Musculoskeletal Injury (Sprain/Strain)
- 14.1.3. Postoperative Pain
- 14.2. Ankylosing Spondylitis
- 14.3. Dysmenorrhea
- 14.4. Fever/Pyrexia
- 14.5. Migraine & Headache
- 14.6. Ophthalmic Pain & Inflammation
- 14.7. Osteoarthritis
- 14.8. Rheumatoid Arthritis
- 15. Non-steroidal Anti-inflammatory Drugs Market, by End User
- 15.1. Ambulatory Surgical Centers
- 15.2. Homecare
- 15.3. Hospitals
- 15.4. Specialty Clinics
- 16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel
- 16.1. Hospital Pharmacies
- 16.2. Online Pharmacies
- 16.3. Retail Pharmacies
- 17. Non-steroidal Anti-inflammatory Drugs Market, by Region
- 17.1. Americas
- 17.1.1. North America
- 17.1.2. Latin America
- 17.2. Europe, Middle East & Africa
- 17.2.1. Europe
- 17.2.2. Middle East
- 17.2.3. Africa
- 17.3. Asia-Pacific
- 18. Non-steroidal Anti-inflammatory Drugs Market, by Group
- 18.1. ASEAN
- 18.2. GCC
- 18.3. European Union
- 18.4. BRICS
- 18.5. G7
- 18.6. NATO
- 19. Non-steroidal Anti-inflammatory Drugs Market, by Country
- 19.1. United States
- 19.2. Canada
- 19.3. Mexico
- 19.4. Brazil
- 19.5. United Kingdom
- 19.6. Germany
- 19.7. France
- 19.8. Russia
- 19.9. Italy
- 19.10. Spain
- 19.11. China
- 19.12. India
- 19.13. Japan
- 19.14. Australia
- 19.15. South Korea
- 20. Competitive Landscape
- 20.1. Market Share Analysis, 2024
- 20.2. FPNV Positioning Matrix, 2024
- 20.3. Competitive Analysis
- 20.3.1. Novartis AG
- 20.3.2. Bayer AG
- 20.3.3. Pfizer Inc.
- 20.3.4. Abbvie, Inc
- 20.3.5. Algen Healthcare Ltd.
- 20.3.6. Allegiant Health
- 20.3.7. Amgen Inc.
- 20.3.8. Amneal Pharmaceuticals LLC
- 20.3.9. Arcutis Biotherapeutics, Inc.
- 20.3.10. Astellas Pharma Inc.
- 20.3.11. AstraZeneca PLC
- 20.3.12. Bristol-Myers Squibb Company
- 20.3.13. Clearsynth Labs Limited
- 20.3.14. Genentech, Inc. by F. Hoffmann-La Roche AG
- 20.3.15. GlaxoSmithKline PLC
- 20.3.16. Johnson & Johnson Services, Inc.
- 20.3.17. Pharbest Pharmaceuticals, Inc.
- 20.3.18. Sanofi S.A.
- 20.3.19. Spectrum Chemical Mfg. Corp.
- 20.3.20. Sun Pharmaceutical Industries Ltd.
- 20.3.21. Teikoku Seiyaku Co., Ltd.
- 20.3.22. Boehringer Ingelheim GmbH
- 20.3.23. Daiichi Sankyo Company, Limited
- 20.3.24. Eisai Co., Ltd.
- 20.3.25. Gilead Sciences, Inc.
- 20.3.26. Eli Lilly and Company
- 20.3.27. Incyte Corporation
- 20.3.28. Merck KGaA
- 20.3.29. Takeda Pharmaceutical Co. Ltd.
- 20.3.30. Dr. Reddy’s Laboratories Ltd.
- 20.3.31. Sandoz International GmbH
- 20.3.32. Viatris Inc.
- 20.3.33. Teva Pharmaceutical Industries Ltd.
- 20.3.34. Verona Pharma plc
- 20.3.35. Hikma Pharmaceuticals PLC
- 20.3.36. EMS S.A.
- 20.3.37. BASF SE
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
